Volume of Disease as a Predictor for Clinical Outcomes in Patients With Melanoma Brain Metastases Treated With Stereotactic Radiosurgery and Immune Checkpoint Therapy
Burke, Aidan M., & Carrasquilla, Michael. (January 2022).
Volume of Disease as a Predictor for Clinical Outcomes in Patients With Melanoma Brain Metastases Treated With Stereotactic Radiosurgery and Immune Checkpoint Therapy.
,
(),
-
. Retrieved from
http://hdl.handle.net/10342/11791
Burke, Aidan M., and Carrasquilla, Michael.
"Volume of Disease as a Predictor for Clinical Outcomes in Patients With Melanoma Brain Metastases Treated With Stereotactic Radiosurgery and Immune Checkpoint Therapy". .
. (),
January 2022.
February 06, 2023.
http://hdl.handle.net/10342/11791.
Chicago:
Burke, Aidan M. and Carrasquilla, Michael,
"Volume of Disease as a Predictor for Clinical Outcomes in Patients With Melanoma Brain Metastases Treated With Stereotactic Radiosurgery and Immune Checkpoint Therapy," , no.
(January 2022),
http://hdl.handle.net/10342/11791 (accessed
February 06, 2023).
AMA:
Burke, Aidan M., Carrasquilla, Michael.
Volume of Disease as a Predictor for Clinical Outcomes in Patients With Melanoma Brain Metastases Treated With Stereotactic Radiosurgery and Immune Checkpoint Therapy. .
January 2022;
():
.
http://hdl.handle.net/10342/11791. Accessed
February 06, 2023.
